Athersys, Inc. (NASDAQ:ATHX) is a leading biopharmaceutical company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications including ischemic stroke, traumatic brain injury, myocardial infarction, acute respiratory distress syndrome, bone marrow transplantation/oncology support and other indications. The Company’s lead program for ischemic stroke has recently completed enrollment (with top-line results pending) in a Phase II/III study in Japan (TREASURE Study) and is currently enrolling patients in a Phase III study in the US and Europe (MASTERS-2 Study).